Eszopiclone | hsa00380 | Tryptophan metabolism | 4.14E-02 | 1 | Q16613 | AANAT | More | |
Eszopiclone | hsa00524 | Neomycin, kanamycin and gentamicin biosynthesis | 2.03E-02 | 1 | P35557 | GCK | More | |
Eszopiclone | hsa00730 | Thiamine metabolism | 1.15E-03 | 2 | Q9Y6K8, P24666 | AK5, ACP1 | More | |
Eszopiclone | hsa00740 | Riboflavin metabolism | 4.03E-02 | 1 | P24666 | ACP1 | More | |
Eszopiclone | hsa01523 | Antifolate resistance | 3.80E-02 | 2 | Q92820, P04818 | GGH, TYMS | More | |
Eszopiclone | hsa03008 | Ribosome biogenesis in eukaryotes | 4.94E-02 | 2 | P19784, P67870 | CSNK2A2, CSNK2B | More | |
Eszopiclone | hsa03050 | Proteasome | 1.40E-02 | 1 | P55036 | PSMD4 | More | |
Eszopiclone | hsa04024 | cAMP signaling pathway | 3.37E-02 | 3 | P63092, P26678, P61586 | GNAS, PLN, RHOA | More | |
Eszopiclone | hsa04072 | Phospholipase D signaling pathway | 2.75E-02 | 3 | P61586, O14986, P63092 | RHOA, PIP5K1B, GNAS | More | |
Eszopiclone | hsa04110 | Cell cycle | 6.80E-03 | 6 | P06493, O75293, P30304, P33981, P42773, P01106 | CDK1, GADD45B, CDC25A, TTK, CDKN2C, MYC | More | |
Eszopiclone | hsa04120 | Ubiquitin mediated proteolysis | 6.89E-03 | 5 | Q14145, Q13042, Q13191, Q15751, Q7Z6Z7 | KEAP1, CDC16, CBLB, HERC1, HUWE1 | More | |
Eszopiclone | hsa04137 | Mitophagy - animal | 2.52E-02 | 2 | P19784, P67870 | CSNK2A2, CSNK2B | More | |
Eszopiclone | hsa04218 | Cellular senescence | 4.79E-02 | 4 | P01106, O75293, P30304, P06493 | MYC, GADD45B, CDC25A, CDK1 | More | |
Eszopiclone | hsa04310 | Wnt signaling pathway | 4.17E-03 | 3 | P61586, P19784, P67870 | RHOA, CSNK2A2, CSNK2B | More | |
Eszopiclone | hsa04510 | Focal adhesion | 4.07E-02 | 3 | O14986, P61586, Q16363 | PIP5K1B, RHOA, LAMA4 | More | |
Eszopiclone | hsa04520 | Adherens junction | 1.38E-04 | 3 | P19784, P67870, P61586 | CSNK2A2, CSNK2B, RHOA | More | |
Eszopiclone | hsa04621 | NOD-like receptor signaling pathway | 4.31E-02 | 4 | P01375, P59665, P59666, P12838 | TNF, DEFA1; DEFA1B, DEFA3, DEFA4 | More | |
Eszopiclone | hsa04640 | Hematopoietic cell lineage | 3.69E-02 | 4 | P21926, P07766, P01730, P09564 | CD9, CD3E, CD4, CD7 | More | |
Eszopiclone | hsa04713 | Circadian entrainment | 4.94E-02 | 2 | P62873, P63092 | GNB1, GNAS | More | |
Eszopiclone | hsa04723 | Retrograde endocannabinoid signaling | 4.94E-02 | 2 | P48169, P62873 | GABRA4, GNB1 | More | |
Eszopiclone | hsa04724 | Glutamatergic synapse | 3.65E-02 | 2 | P63092, P62873 | GNAS, GNB1 | More | |
Eszopiclone | hsa04726 | Serotonergic synapse | 2.52E-02 | 2 | P63092, P62873 | GNAS, GNB1 | More | |
Eszopiclone | hsa04940 | Type I diabetes mellitus | 1.87E-02 | 2 | P48023, P01375 | FASLG, TNF | More | |
Eszopiclone | hsa04950 | Maturity onset diabetes of the young | 2.03E-02 | 1 | P35557 | GCK | More | |
Eszopiclone | hsa04972 | Pancreatic secretion | 3.65E-02 | 2 | P63092, P61586 | GNAS, RHOA | More | |
Eszopiclone | hsa05032 | Morphine addiction | 9.04E-05 | 5 | P62873, P48169, P78334, P63092, P32298 | GNB1, GABRA4, GABRE, GNAS, GRK4 | More | |
Eszopiclone | hsa05142 | Chagas disease | 2.26E-02 | 3 | P01375, P30679, P48023 | TNF, GNA15, FASLG | More | |
Eszopiclone | hsa05143 | African trypanosomiasis | 2.72E-02 | 2 | P01375, P48023 | TNF, FASLG | More | |
Eszopiclone | hsa05150 | Staphylococcus aureus infection | 1.83E-02 | 3 | P59665, P59666, P12838 | DEFA1; DEFA1B, DEFA3, DEFA4 | More | |
Eszopiclone | hsa05163 | Human cytomegalovirus infection | 2.09E-02 | 4 | P62873, P61586, P63092, P61769 | GNB1, RHOA, GNAS, B2M | More | |
Eszopiclone | hsa05171 | Coronavirus disease - COVID-19 | 4.47E-02 | 2 | Q9UHA3, O14786 | RSL24D1, NRP1 | More | |
Eszopiclone | hsa05216 | Thyroid cancer | 3.80E-02 | 2 | P01106, O75293 | MYC, GADD45B | More | |
Eszopiclone | hsa05223 | Non-small cell lung cancer | 1.39E-02 | 3 | P10826, Q9HC35, O75293 | RARB, EML4, GADD45B | More | |
Eszopiclone | hsa05235 | PD-L1 expression and PD-1 checkpoint pathway in cancer | 1.09E-02 | 4 | P07766, P06239, Q9HC35, P01730 | CD3E, LCK, EML4, CD4 | More | |
Eszopiclone | hsa05330 | Allograft rejection | 2.72E-02 | 2 | P48023, P01375 | FASLG, TNF | More | |
Eszopiclone | hsa05332 | Graft-versus-host disease | 3.70E-02 | 2 | P48023, P01375 | FASLG, TNF | More | |
Eszopiclone | hsa05340 | Primary immunodeficiency | 1.28E-03 | 4 | P01730, P11912, P07766, P06239 | CD4, CD79A, CD3E, LCK | More | |
Zopiclone | hsa00380 | Tryptophan metabolism | 4.14E-02 | 1 | Q16613 | AANAT | More | |
Zopiclone | hsa00524 | Neomycin, kanamycin and gentamicin biosynthesis | 2.03E-02 | 1 | P35557 | GCK | More | |
Zopiclone | hsa00730 | Thiamine metabolism | 1.15E-03 | 2 | Q9Y6K8, P24666 | AK5, ACP1 | More | |
Zopiclone | hsa00740 | Riboflavin metabolism | 4.03E-02 | 1 | P24666 | ACP1 | More | |
Zopiclone | hsa01523 | Antifolate resistance | 3.80E-02 | 2 | Q92820, P04818 | GGH, TYMS | More | |
Zopiclone | hsa03050 | Proteasome | 1.40E-02 | 1 | P55036 | PSMD4 | More | |
Zopiclone | hsa04110 | Cell cycle | 6.80E-03 | 6 | P06493, O75293, P30304, P33981, P42773, P01106 | CDK1, GADD45B, CDC25A, TTK, CDKN2C, MYC | More | |
Zopiclone | hsa04120 | Ubiquitin mediated proteolysis | 6.89E-03 | 5 | Q14145, Q13042, Q13191, Q15751, Q7Z6Z7 | KEAP1, CDC16, CBLB, HERC1, HUWE1 | More | |
Zopiclone | hsa04218 | Cellular senescence | 4.79E-02 | 4 | P01106, O75293, P30304, P06493 | MYC, GADD45B, CDC25A, CDK1 | More | |
Zopiclone | hsa04621 | NOD-like receptor signaling pathway | 4.31E-02 | 4 | P01375, P59665, P59666, P12838 | TNF, DEFA1; DEFA1B, DEFA3, DEFA4 | More | |
Zopiclone | hsa04640 | Hematopoietic cell lineage | 3.69E-02 | 4 | P21926, P07766, P01730, P09564 | CD9, CD3E, CD4, CD7 | More | |
Zopiclone | hsa04940 | Type I diabetes mellitus | 1.87E-02 | 2 | P48023, P01375 | FASLG, TNF | More | |
Zopiclone | hsa04950 | Maturity onset diabetes of the young | 2.03E-02 | 1 | P35557 | GCK | More | |
Zopiclone | hsa05032 | Morphine addiction | 1.09E-02 | 2 | P78334, P32298 | GABRE, GRK4 | More | |
Zopiclone | hsa05142 | Chagas disease | 2.26E-02 | 3 | P01375, P30679, P48023 | TNF, GNA15, FASLG | More | |
Zopiclone | hsa05143 | African trypanosomiasis | 2.72E-02 | 2 | P01375, P48023 | TNF, FASLG | More | |
Zopiclone | hsa05150 | Staphylococcus aureus infection | 1.83E-02 | 3 | P59665, P59666, P12838 | DEFA1; DEFA1B, DEFA3, DEFA4 | More | |
Zopiclone | hsa05171 | Coronavirus disease - COVID-19 | 4.47E-02 | 2 | Q9UHA3, O14786 | RSL24D1, NRP1 | More | |
Zopiclone | hsa05216 | Thyroid cancer | 3.80E-02 | 2 | P01106, O75293 | MYC, GADD45B | More | |
Zopiclone | hsa05223 | Non-small cell lung cancer | 1.39E-02 | 3 | P10826, Q9HC35, O75293 | RARB, EML4, GADD45B | More | |
Zopiclone | hsa05235 | PD-L1 expression and PD-1 checkpoint pathway in cancer | 1.09E-02 | 4 | P07766, P06239, Q9HC35, P01730 | CD3E, LCK, EML4, CD4 | More | |
Zopiclone | hsa05330 | Allograft rejection | 2.72E-02 | 2 | P48023, P01375 | FASLG, TNF | More | |
Zopiclone | hsa05332 | Graft-versus-host disease | 3.70E-02 | 2 | P48023, P01375 | FASLG, TNF | More | |
Zopiclone | hsa05340 | Primary immunodeficiency | 1.28E-03 | 4 | P01730, P11912, P07766, P06239 | CD4, CD79A, CD3E, LCK | More | |